Call for Papers  

Article Details

Review Article

GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD

[ Vol. 30 , Issue. 2 ]


Haoran Jiang and Linquan Zang*   Pages 100 - 114 ( 15 )


Non-alcoholic fatty liver disease (NAFLD) has recently emerged as a global public health concern. Currently, the cornerstone of NAFLD treatment is lifestyle modification and, if necessary, weight loss. However, compliance is a challenge, and this approach alone may not be sufficient to halt and treat the more serious disease development, so medication is urgently needed. Nevertheless, no medicines are approved to treat NAFLD. Glucagon-like peptide-1 (GLP-1) is an enteropeptide hormone that inhibits glucagon synthesis, promotes insulin secretion, and delays gastric emptying. GLP-1 has been found in recent studies to be beneficial for the management of NAFLD, and the marketed GLP-1 agonist drugs have different degrees of effectiveness for NAFLD while lowering blood glucose. In this article, we review GLP-1 and its physiological roles, the pathogenesis of NAFLD, the correlation between NAFLD and GLP-1 signaling, and potential strategies for GLP-1 treatment of NAFLD.


Glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance, steatosis.


Read Full-Text article